Primary Generalized Tonic-Clonic Seizures

Neurology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Xenon Pharmaceuticals
1 program
1
XEN1101Phase 31 trial
Active Trials
NCT05667142Recruiting160Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Xenon PharmaceuticalsXEN1101

Clinical Trials (1)

Total enrollment: 160 patients across 1 trials

NCT05667142Xenon PharmaceuticalsXEN1101

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Start: Feb 2023Est. completion: Jun 2027160 patients
Phase 3Recruiting

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
6h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
6h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
6h ago

Director of Finance

CoMind
London, UK
6h ago

Electronics Engineering Manager

CoMind
London, UK
6h ago

Director of Information Technology

Zavation Medical Products
6h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 160 patients
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)